. 2022 Nov 15;12(11):2797. doi: 10.3390/diagnostics12112797

Table 3.

Midazolam concentration according to the genotype and stratified by sex.

Sex	Genotype	N (%) 55 (100)	Midazolam at 3 h	p-Value	Midazolam at 24 h	p-Value
Sex	Genotype	N (%) 55 (100)	Median (Q₂₅–Q₇₅)	p-Value	Median (Q₂₅–Q₇₅)	p-Value
	CYP3A4/rs2740574
	Dominant
Male	CC+CT	6 (17.6)	107.7 (0.00–342.6)	0.9	0.00 (0.00–195.2)	0.7
	TT	28 (82.4)	27.4 (0.00–301.3)	0.9	0.00 (0.00–133.9)	0.7
Female	CC+CT	1 (5)	NC	0.3	NC	1
	TT	20 (95)	288.4 (0.00–563.6)	0.3	0.00 (0.00–133.2)	1
	Recessive
Male	CC	0	NC	0.4	NC	0.6
	CT+TT	34 (100)	39.21 (0.00–322.5)	0.4	0.00 (0.00–168.9)	0.6
Female	CC	0	NC	NC	NC	NC
	CT+TT	21 (100)	275.6 (0.00–548.0)	NC	0.00 (0.00–99.1)	NC
	CYP3A5/rs776746
	Dominant
Male	TT+TC	17 (50)	0.00 (0.00–146.8)	0.07	0.00 (0.00–0.00)	0.4
	CC	17 (50)	140.3 (0.00–342.6)	0.07	0.00 (0.00–171.0)	0.4
Female	TT+TC	10 (47.6)	0.00 (0.00–204.3)	0.002 *	0.00 (0.00–79.0)	0.3
	CC	11 (52.4)	459.0 (296.9–789.7)	0.002 *	0.00 (0.00–171.6)	0.3
	Recessive
Male	TT	2 (6)	104.7 (0.00–209.5)	0.9	84.4 (0.00–168.9)	0.9
	TC+CC	32 (94)	39.2 (0.00–332.5)	0.9	0.00 (0.00–135.0)	0.9
Female	TT	0	NC	NC	NC	NC
	TC+CC	21 (100)	275.6 (0.00–548.0)	NC	0.00 (0.00–99.1)	NC

* Statistical significance was calculated using the nonparametric Mann–Whitney U test; NC = Not calculable.